Abstract
Twenty-three patients with acute nor1 lymphocytic leukemia (ANLL), were treated with a single-6 day course of Mitoxantrone 6mg/m2/day, Etoposide 80mg/m2 day and intermediate dose Cytarabine (ara-C) Ig/m2/day (MEC). Patients who achieved complete remission (CR) were submitted to a 4-day-course of MEC as consolidation. Seventeen patients (73.9% obtained CR, five patients (22.7% were resistant to the treatment and one patient died during induction. Median remission duration was 11 months; overall median survival was 16 months. Relapses occurred in 11 patients; eight patients are still alive: 6 in 1st, 2 in 2nd CR (mean survival 20.1 months, range 17-26). All patients experienced severe myelosuppression comparable to that observed after classical induction cycles including ara-C in continuous intravenous infusion; none, however, died of infection. Non-hematologic toxicity was minimal; in particular, neurotoxicity was not observed. According to our results, the MEC regimen, which was previously demonstrated to be active in refractory patients, represents an effective induction treatment in ANLL, with an acceptable toxicity.
| Original language | English |
|---|---|
| Pages (from-to) | 447-451 |
| Number of pages | 5 |
| Journal | Leukemia and Lymphoma |
| Volume | 19 |
| Issue number | 5-6 |
| DOIs | |
| Publication status | Published - 1995 |
Fingerprint
Keywords
- Acute myeloid leukemia
- Intermediate dose cytarabine
- Mitoxantrone
- Remission
- Survival
ASJC Scopus subject areas
- Hematology
- Oncology
- Cancer Research
Cite this
MEC (mitoxantrone, etoposide and intermediate dose cytarabine) : An effective induction regimen for previously untreated acute non-lymphocytic leukemia. / Visani, G.; Petti, M. C.; Cenacchi, A.; Manfroi, S.; Tosi, P.; Spadea, A.; Latagliata, R.; Amadori, S.; Mandelli, F.; Tura, S.
In: Leukemia and Lymphoma, Vol. 19, No. 5-6, 1995, p. 447-451.Research output: Contribution to journal › Article
}
TY - JOUR
T1 - MEC (mitoxantrone, etoposide and intermediate dose cytarabine)
T2 - An effective induction regimen for previously untreated acute non-lymphocytic leukemia
AU - Visani, G.
AU - Petti, M. C.
AU - Cenacchi, A.
AU - Manfroi, S.
AU - Tosi, P.
AU - Spadea, A.
AU - Latagliata, R.
AU - Amadori, S.
AU - Mandelli, F.
AU - Tura, S.
PY - 1995
Y1 - 1995
N2 - Twenty-three patients with acute nor1 lymphocytic leukemia (ANLL), were treated with a single-6 day course of Mitoxantrone 6mg/m2/day, Etoposide 80mg/m2 day and intermediate dose Cytarabine (ara-C) Ig/m2/day (MEC). Patients who achieved complete remission (CR) were submitted to a 4-day-course of MEC as consolidation. Seventeen patients (73.9% obtained CR, five patients (22.7% were resistant to the treatment and one patient died during induction. Median remission duration was 11 months; overall median survival was 16 months. Relapses occurred in 11 patients; eight patients are still alive: 6 in 1st, 2 in 2nd CR (mean survival 20.1 months, range 17-26). All patients experienced severe myelosuppression comparable to that observed after classical induction cycles including ara-C in continuous intravenous infusion; none, however, died of infection. Non-hematologic toxicity was minimal; in particular, neurotoxicity was not observed. According to our results, the MEC regimen, which was previously demonstrated to be active in refractory patients, represents an effective induction treatment in ANLL, with an acceptable toxicity.
AB - Twenty-three patients with acute nor1 lymphocytic leukemia (ANLL), were treated with a single-6 day course of Mitoxantrone 6mg/m2/day, Etoposide 80mg/m2 day and intermediate dose Cytarabine (ara-C) Ig/m2/day (MEC). Patients who achieved complete remission (CR) were submitted to a 4-day-course of MEC as consolidation. Seventeen patients (73.9% obtained CR, five patients (22.7% were resistant to the treatment and one patient died during induction. Median remission duration was 11 months; overall median survival was 16 months. Relapses occurred in 11 patients; eight patients are still alive: 6 in 1st, 2 in 2nd CR (mean survival 20.1 months, range 17-26). All patients experienced severe myelosuppression comparable to that observed after classical induction cycles including ara-C in continuous intravenous infusion; none, however, died of infection. Non-hematologic toxicity was minimal; in particular, neurotoxicity was not observed. According to our results, the MEC regimen, which was previously demonstrated to be active in refractory patients, represents an effective induction treatment in ANLL, with an acceptable toxicity.
KW - Acute myeloid leukemia
KW - Intermediate dose cytarabine
KW - Mitoxantrone
KW - Remission
KW - Survival
UR - http://www.scopus.com/inward/record.url?scp=0028972612&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=0028972612&partnerID=8YFLogxK
U2 - 10.3109/10428199509112203
DO - 10.3109/10428199509112203
M3 - Article
C2 - 8590845
AN - SCOPUS:0028972612
VL - 19
SP - 447
EP - 451
JO - Leukemia and Lymphoma
JF - Leukemia and Lymphoma
SN - 1042-8194
IS - 5-6
ER -